TRICARE Pharmacy Program Medical Necessity Form for Nasal Corticosteroids

This form applies to the TRICARE Mail Order Pharmacy (TMOP) and the TRICARE Retail Pharmacy Program (TRRx) and may be found on the TRICARE Pharmacy website at www.tricare.osd.mil/pharmacy/medical-nonformulary.cfm. The medical necessity criteria outlined on this form also apply at Military Treatment Facilities (MTFs). The form must be completed and signed by the prescriber.

- Flunisolide (Nasarel and generic), fluticasone (Flonase), and mometasone (Nasonex) are the formulary nasal corticosteroids on the DoD Uniform Formulary. Beclomethasone (Beconase AQ), budesonide (Rhinocort Aqua), and triamcinolone (Nasacort AQ) are non-formulary, but available to most beneficiaries at a \$22 cost share.
- You do NOT need to complete this form in order for non-active duty beneficiaries (spouses, dependents, and retirees) to obtain nonformulary medications at the \$22 non-formulary cost share. The purpose of this form is to provide information that will be used to determine if the use of a non-formulary medication instead of a formulary medication is medically necessary. If a non-formulary medication is determined to be medically necessary, non-active duty beneficiaries may obtain it at the \$9 formulary cost share.

Latest revision: January 2006

Active duty service members may not fill prescriptions for a non-formulary medication unless it is determined to be medically necessary. There is no cost share for active duty service members at any DoD pharmacy point of service.

Щ	• T	e prescription is to be filingh the TRICARE Mail Crmacy, check here The completed form and the hay be faxed to 1-877-283-602-586-3915 or The patient may attach the porm to the prescription and	ne prescriptio 3-8075 or completed	RETAIL	• The provider may call: 1-866-684-4488 OR • The completed form may be	MTH	Non-formulary medications are available at MTFs only if both of the following are true: The prescription is written by a military provider or, at the discretion of the MTF, a civilian provider to whom the patient was referred by the MTF. The non-formulary medication is determined to be medically necessary. Please contact your local MTF for more	
	Е	xpress Scripts, P.O. Bo Phoenix, AZ 85072-9954	x 52150,		faxed to 1-866-684-4477		information. There are no cost shares at MTFs.	
There is no expiration date for approved medical necessity determinations.								
Ste	Please complete patient and physician information (Please Print)							
1		Patient Name: Address:			Physician Name: Address:			
		Address.			Address.			
		Sponsor ID #			Phone #:			
					Secure Fax #		_	
Ste	Step 1. Please explain why the patient cannot be treated with any of the formulary alternatives:							
2	2	Please indicate which of the reasons below (1-3) applies to each of the formulary alternatives listed in the table. You MUST circle a reason AND supply a written clinical explanation specific for EACH formulary alternative.						
		Formulary Altern	ative R	easor	1	Clin	ical Explanation	
		Flunisolide (Nasarel or generic)		1 2 3				
		generic						
		Fluticasone (Flonase)		1 2 3				
				1 2 3				
		Fluticasone (Flonase) Mometasone (Nasonex	x)	1 2 3	sing a formulary alternative a	are:		
		Fluticasone (Flonase) Mometasone (Nasonex Acceptable clinical re	easons for	1 2 3	sing a formulary alternative a		reaction).	
		Fluticasone (Flonase) Mometasone (Nasonex Acceptable clinical red) The formulary alter The patient has ex	easons for	1 2 3 not us ntraine	dicated (e.g., due to a hyperser ant adverse effects (e.g., persis	nsitivity stent ep	pistaxis, pharyngitis, or significant nasal	
		Fluticasone (Flonase) Mometasone (Nasonex Acceptable clinical red) The formulary alter The patient has ex	easons for rnative is coperienced sormulary al	not unitraine	dicated (e.g., due to a hyperser ant adverse effects (e.g., persiste, and is not expected to expe	nsitivity stent ep	•	
Ste	•	Fluticasone (Flonase) Mometasone (Nasonex Acceptable clinical re 1. The formulary alter 2. The patient has ex irritation) with the feature of the formulary alter 3. The formulary alter	easons for rnative is comperienced sommulary alternative resu	not us ontraine ignificative ernative lted in	dicated (e.g., due to a hyperser ant adverse effects (e.g., persiste, and is not expected to expet therapeutic failure.	nsitivity stent ep erience	pistaxis, pharyngitis, or significant nasal	